Put companies on watchlist
Carl Zeiss Meditec AG
ISIN: DE0005313704
WKN: 531370
Curious about what AI knows about Carl Zeiss Meditec? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Carl Zeiss Meditec AG · ISIN: DE0005313704 · EQS - adhoc news (42 News)
Country: Germany · Primary market: Germany · EQS NID: 2117766
15 April 2025 08:57AM

Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25


EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results/Quarter Results
Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25

15-Apr-2025 / 08:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
 
Jena, April 15, 2025
In the second quarter of fiscal year 2024/25 ending March 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of around EUR 560 million (previous year: EUR 472.1 million), based on preliminary data, an increase of around 19%. This includes a contribution of around EUR 54 million from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), which has been consolidated for the first time since April 2024. Excluding this contribution, revenue growth would have amounted to around 7%. Earnings before interest, taxes and amortization on intangible assets from purchase price allocations (EBITA) reached around EUR 78 million (previous year: EUR 67.2 million). Earnings per share resulted in EUR 0.52 (previous year: EUR 0.52).

The increase in revenue and earnings in the second quarter of 2024/25 has been driven in particular by stronger than previously anticipated growth in the consumables business for refractive surgery in China.

After 6 months 2024/25, revenue reached around EUR 1,050 million (previous year: EUR 947.2 million) and EBITA reached EUR 114 million (previous year: EUR 113.2 million). Earnings per share came in at EUR 0.70 (previous year: EUR 0.94).

For fiscal year 2024/25, Carl Zeiss Meditec AG expects moderate revenue growth (against a previous year’s base of EUR 2,066.1 million) as well as a stable to slightly higher EBITA (against a previous year’s base of EUR 248.9 million). In light of current macro-economic and geopolitical uncertainties regarding the introduction of trade tariffs by the United States of America and incremental currency risks a more precise update to the forecast cannot currently be provided.

The half year report 2024/25 will be published on May 13, 2025.
 
 

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.med@zeiss.com

 

 

 

 

 

 

 

 

 



End of Inside Information

15-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2117766

 
End of Announcement EQS News Service

2117766  15-Apr-2025 CET/CEST

Visual performance / price development - Carl Zeiss Meditec AG
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.